Latest Articles
-
Will Pfizer Stock See Higher Levels Post Q1 Earnings?
Pfizer (NYSE: PFE) is scheduled to report its Q1 2023 results on Tuesday, May 2, and we expect it to see higher levels, with its revenue and earnings expected to exceed the consensus estimates. Its Covid-19 vaccine and the antiviral pill will see...
-
Is Pfizer Stock Undervalued At $40?
Pfizer stock (NYSE: PFE) has seen a fall of 21% this year, compared with 2% returns for the broader S&P500 index. Pfizer stock has been weighed down due to an anticipated decline of over 30% in its 2023 sales, primarily due to lower sales o...
-
This Logistics Company Appears To Be A Better Pick Over Pfizer Stock
We believe that FedEx stock (NYSE: FDX) is a better pick than the pharmaceutical giant Pfizer stock (NYSE: PFE), given its better prospects. Although these companies are from different sectors, we compare them because they have a similar re...
-
What To Expect From Pfizer’s Q4?
Pfizer (NYSE: PFE) is scheduled to report its Q4 2022 results on Tuesday, January 31, and we expect it to see little movement, with its revenue falling slightly ahead, but earnings likely missing the consensus estimates. Its Covid-19 vaccine and ...
-
Is Pfizer Stock A Better Pick Over This Pharmaceuticals Bellwether?
We believe that Pfizer stock (NYSE: PFE) is currently a better pick than its peer, Johnson & Johnson stock (NYSE: JNJ), given its relatively lower valuation of 3.1x trailing revenues, compared to 4.9x for J&J. We think that this val...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) posted a stronger-than-expected set of Q3 2022 results. Although revenue declined by about 6% versus last year to $22.6 billion, it came in ahead of estimates. Adjusted earnings stood at $1.78 per share, up 40% versus la...
-
Should You Buy Pfizer Stock Ahead of Its Q3 Results?
Pfizer (NYSE: PFE) is scheduled to report its Q3 2022 results on Tuesday, November 1, and we expect it to post revenue and earnings above the consensus estimates. Its Covid-19 vaccine and the antiviral pill will continue to aid revenue growth. Ho...
-
Pfizer’s Peer Appears To Be A Better Pharmaceuticals Pick
We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer, Pfizer stock (NYSE: PFE), despite its higher valuation of 3.8x trailing revenues vs. 2.5x for Pfizer. This valuation gap can be attributed to Merck’s su...
-
Should You Buy Pfizer Stock After An Upbeat Q2?
Pfizer stock (NYSE: PFE) reported its Q2 results last week, with revenue and earnings comfortably above ours and the street estimates. However, PFE stock has seen a fall of around 5% in a week as the company didn’t raise its full-year ou...
-
Should You Buy Pfizer Stock Ahead of Its Q2 Results?
Pfizer (NYSE: PFE) is scheduled to report its Q2 2022 results on Thursday, July 28, and we expect it to post revenue and earnings well above the consensus estimates. Its Covid-19 vaccine and the antiviral pill will continue to drive revenue growt...
-
Should You Buy, Sell, Or Hold Pfizer Stock At $52?
After an 8% fall year-to-date, at the current levels, we believe Pfizer stock (NYSE: PFE) has some room for growth. PFE stock fell from $57 in early January to $52 now. The YTD -8% return for PFE marks an outperformance with -19% returns for th...
-
Here’s A Better Pick Over FedEx Stock
We think that Pfizer stock (NYSE: PFE) currently is a better pick compared to FedEx stock (NYSE: FDX), despite it being the more expensive of the two, trading at 3.3x trailing revenues compared to 0.6x for FedEx. The gap in the valuation of ...
-
Company Of The Day: Pfizer
What? Pfizer (NYSE:PFE) plans to acquire Biohaven Pharmaceutical, a company that specializes in migraine treatments, in a deal valued at about $11.6 billion. Why? Pfizer is flush with cash from its Covid-19 vaccine and is looking at acquisiti...
-
What To Expect From Pfizer’s Q1?
Pfizer (NYSE: PFE) is scheduled to report its Q1 2022 results on Tuesday, May 3. We expect the company to likely post revenue and earnings below the consensus estimates. The revenue from its Covid-19 vaccine and antiviral pill sales may be lower ...
-
Company Of The Day: Pfizer
What? A recently published study from Israel on booster shots of Pfizer (NYSE:PFE) and its partner BioNTech’s Covid-19 vaccine indicates that a fourth dose of the vaccine (second booster) lowered the risk of severe disease in the elderly, ...
